AVI Biopharma, the Bothell, WA-based developer of RNA-based therapies, said today it has hired Chris Garabedian as its new president and CEO. Garabedian, 44, previously was a vice president of corporate development with Summit, NJ-based Celgene (NASDAQ: [[ticker:CELG]]). AVI has had an opening for a permanent CEO since April, when Les Hudson was ousted in a shareholder uprising. Garabedian starts on January 1, and will replace AVI interim president and CEO David Boyle, who will continue with the company as chief financial officer and senior vice president.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
